GlassScriptPhysician profile
Regan E Heagen
NPI 1407327315
$7,817.99
in general payments reported to CMS, 2019-2025
39 companies · $2,060 in 2025
The $2,060 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,084 · 2022: $1,436 · 2023: $1,178 · 2024: $2,061 · 2025: $2,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,243.34 | 2021-2025 | |
| Novo Nordisk INC | $641.19 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $563.83 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $513.80 | 2021-2025 | Caplyta |
| Pfizer INC. | $452.42 | 2021-2025 | |
| Lilly USA, LLC | $430.88 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $419.32 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $259.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $239.95 | 2021-2024 | Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $187.91 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.11 | 2021-2025 | Xifaxan |
| Amgen INC. | $156.51 | 2021-2023 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $132.60 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $125.78 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $121.62 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.92 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $108.91 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $102.47 | 2024-2025 | Auvelity, Symbravo |
| Abbott Laboratories | $86.20 | 2024-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $82.24 | 2024-2025 | Tymlos |
| Sumitomo Pharma America, INC. | $81.83 | 2024-2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $70.03 | 2024-2025 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $64.87 | 2024-2025 | Spravato |
| Currax Pharmaceuticals LLC | $46.86 | 2021-2024 | Contrave |
| Astellas Pharma US INC | $42.91 | 2021-2024 | Veozah |
| Lundbeck LLC | $42.59 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $42.48 | 2021-2022 | |
| Shield Therapeutics INC | $37.20 | 2025 | |
| Exeltis, USA INC. | $35.06 | 2021-2022 | |
| Harmony Biosciences LLC | $32.88 | 2023-2024 | Wakix |
| Xeris Pharmaceuticals, INC. | $27.42 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $26.87 | 2021 | |
| Dexcom, INC. | $18.70 | 2023 | Dexcom G6 Transmitter |
| Biomarin Pharmaceutical INC. | $18.03 | 2024 | Voxzogo 1.2mg |
| Novartis Pharmaceuticals Corporation | $15.00 | 2021 | |
| Bausch Health US, LLC | $14.75 | 2022 | |
| Athena Bioscience, LLC | $14.30 | 2023 | Nexiclon Xr |
| Phadia US INC. | $14.03 | 2024 | Immunocap |
| Amneal Pharmaceuticals LLC | $13.76 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regan Heagen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.